PHILADELPHIA -- An oral, non-addictive sodium channel blocker safely relieved moderate-to-severe acute pain following surgery, according to phase III data that could support regulatory approval.
LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Asana BioSciences announced today positive topline results from a Phase 1b study evaluating the treatment of pruritus associated with atopic dermatitis ...
Channel Therapeutics Corporation, a clinical-stage biotechnology company focused on non-opioid pain treatments, expressed encouragement regarding Vertex Pharmaceuticals' recent Phase 2 data for ...
Halneuron, a NaV 1.7 sodium channel inhibitor, is being tested for chemotherapy-induced neuropathic pain, offering a potential opioid alternative. Previous trials showed Halneuron significantly ...
Two decades ago, when two genetic mutations were discovered in Asia that gave scientists a better idea of how pain sensations traveled through the body and identified which part of the nervous system ...
This article examines emerging non-opioid strategies for chronic pain, from targeted ion-channel drugs and anti-inflammatory ...
In its second large deal of the calendar year, Neurocrine Biosciences Inc. acquired the rights to Xenon Pharmaceutical Inc.’s selective sodium channel inhibitor for treating epileptic encephalopathy.
A derivative of the diuretic drug amiloride (Midamor) blocked key inflammatory pathways in mouse models of psoriasis, including xenografts of psoriatic human skin, as well as in cultured patient skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results